title: Outcome of renal transplantation at Oregon Health Sciences University: 1982 to 1990.
abstract: 1. Graft survival increased over the 4 periods between 1982 and 1990 (82-84, 85-86, 87-88, 89-90). The largest increase was in the 89-90 period. 2. Immunosuppression was the key to improved outcome. Cadaveric graft recipients given OKT3 induction plus triple therapy with cyclosporine, azathioprine, and prednisone had significantly better graft survival compared with all other drug combinations. Other factors were improved patient selection, donor management, and outpatient care. 3. Mean serum creatinine levels did not change after cyclosporine was introduced for immunosuppression. The mean serum creatinine level was approximately 1.7 mg/dl at 3 months, 6 months, and 12 months post-transplantation in all 4 periods. 4. Living-related donor outcome was significantly better than cadaveric donor outcome. Half-life for 2-haplotype-matched kidneys was 37 years compared with 12 years for 1-haplotype matches and 6.5 years for cadaveric kidneys. 5. Immediate function and a rejection-free first month were both associated with significantly improved graft survival. 6. Neither peak PRA nor graft number (1st vs regraft) correlated with graft survival. Highly sensitized (PRA greater than 50%) patients and regrafted patients fared as well as less sensitized (PRA less than or equal to 50%) and first graft recipients. This outcome was attributed to a sensitive crossmatch. Because of the crossmatch, highly sensitized patients received much better HLA matches. 7. The incidence of early rejection and delayed function declined significantly between the earliest and latest periods. Improved immunosuppression, donor management, and renal preservation were cited as contributing factors.
authors.affiliation: Oregon Health Sciences University, Portland.
authors.forename: D J
authors.initials: DJ
authors.lastname: Norman
authors.forename: W M
authors.initials: WM
authors.lastname: Bennett
authors.forename: P J
authors.initials: PJ
authors.lastname: Wetzsteon
authors.forename: T
authors.initials: T
authors.lastname: Hefty
authors.forename: M M
authors.initials: MM
authors.lastname: Meyer
authors.forename: D
authors.initials: D
authors.lastname: Tolzman
authors.forename: M
authors.initials: M
authors.lastname: Seely
authors.forename: M
authors.initials: M
authors.lastname: Millhollen
authors.forename: J M
authors.initials: JM
authors.lastname: Barry
mesh_terms: D000206:Actuarial Analysis; D002102:Cadaver; D005500:Follow-Up Studies; D006085:Graft Survival; D006650:Histocompatibility Testing / Q000706:statistics & numerical data; D006801:Humans; D007165:Immunosuppression Therapy / Q000706:statistics & numerical data; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000601:surgery*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000706:statistics & numerical data*; D009922:Oregon; D011183:Postoperative Complications / Q000401:mortality*; D015996:Survival Rate